Abstract:Objectives The aim of this study was to investigate plasma ADAMTS-13 activity in patients with proliferative lupus nephritis and to evaluate the role of clinical, laboratory and pathological features, especially the vascular lesions in lupus nephritis. Methods Plasma samples from 163 class III and IV lupus nephritis patients confirmed by biopsy examinations and 98 normal controls were collected. ADAMTS-13 activity was evaluated by a residual collagen binding assay. IgG autoantibodies against ADAMTS-13 were detected by ELISA using recombinant ADAMTS-13 as a solid-phase ligand. Levels of vWF were measured by ELISA. Their associations with clinical, laboratory and pathological features were further assessed. Results Plasma ADAMTS-13 activity in lupus nephritis patients was significantly lower than that in normal controls (84 ± 21% vs. 90 ± 13%, p = 0.005). IgG ADAMTS-13 autoantibodies were detected in only three patients. The plasma level of vWF was significantly higher in the lupus nephritis group than in normal controls (1.00 ± 0.79 vs. 0.70 ± 0.30, p = 0.025). Plasma ADAMTS-13 activity was negatively correlated with the level of serum creatinine and proteinuria ( r = –0.354, p < 0.001; r = –0.200, p = 0.011, respectively). Patients with a higher level of ADAMTS-13 activity had significantly higher levels of factor H (401.51 ± 183.01 µg/ml vs. 239.02 ± 155.45 µg/ml, p = 0.005). Plasma ADAMTS-13 activity was negatively associated with total pathological AI scores ( r = –0.326, p < 0.001), endocapillary hypercellularity ( r = –0.419, p < 0.001), cellular crescents ( r = –0.274, p < 0.001), subendothelial hyaline deposits ( r = –0.266, p = 0.001), interstitial inflammatory cell infiltration ( r = –0.304, P < 0.001), tubular atrophy ( r = –0.199, p = 0.011), acute glomerular vascular lesions ( r = –0.344, p < 0.001) and acute renal vascular lesions ( r = –0.338, p < 0.001). No association was found between level of vWF and plasma ADAMTS-13 activity ( r = 0.033, p = 0.671). Low level of ADAMTS-13 activity was a risk factor for renal outcomes ( p = 0.039, HR = 0.047, 95% CI: 0.120–1.005). Conclusions Decreased ADAMTS-13 activity was found in patients with proliferative lupus nephritis, and plasma ADAMTS-13 activity was closely associated with renal injury indices, especially pathological vascular scores. The role of ADAMTS-13 in the disease remains to be further investigated.

[The Association of Von Willebrand Factor and Von Willebrand Factor-Cleaving Protease in Systemic Lupus Erythematosus].

The Correlation Between the Serum Collagen Type Ⅳ and Laminin Levels and Disease Activity in Systemic Lupus Erythematosus

Clinical Implication of Levels of Serum Collagen Type Ⅳ and Laminin in Systemic Lupus Erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

[Clinical Significance of CD4+CD25+ T Cells in Peripheral Blood of Patients in Systemic Lupus Erythematosus].

Limited Association between Antibodies to Oxidized Low-Density Lipoprotein and Vascular Affection in Patients with Established Systemic Lupus Erythematosus

Expression of P-selectin in peripheral blood of patients with systemic lupus erythematosus and its clinical significance

Expressions of BAFF/BAFF Receptors and Their Correlation with Disease Activity in Chinese SLE Patients

Elevated Urinary and Blood Vascular Cell Adhesion Molecule-1 as Potential Biomarkers for Active Systemic Lupus Erythematosus: A Meta-analysis

The Clinical Significance of Soluble Axl and Tyro3 Receptor Tyrosine Kinase in Systemic Lupus Erythematosus

Clinical evaluation of testing serum β_2-GPI/ox-LDL complexes in patients with systemic lupus erythematosus

Platelet Distribution Width As a Novel Indicator of Disease Activity in Systemic Lupus Erythematosus

The Influence of Immunosuppressive Therapy on Titers of Anticardio-Lipin Antibodies in Systemic Lupus Erythematosus

Correlation of Serum B Cell Activating Factor with Disease Activity in Patients with Systemic Lupus Erythematosus

The Correlation Between the Global Disease Activity of SLE and the Clinical Manifestation and Immune Sera Test

Association of Serum Level of Apolipoprotein M with Disease Activity in Systemic Lupus Erythematosus

Plasma Adamts-13 Abnormalities in Active Proliferative Lupus Nephritis: A Large Cohort Study from China

Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.

Expression and significance of erythrocyte complement receptor type 1 in patients with systemic lupus erythematosus

Anticarrliolipin Antibodies and Blood Coagulation Changes an Pstiemts with Systemic Lupus Erythematosns